Wip1 knockout inhibits the proliferation and enhances the migration of bone marrow mesenchymal stem cells

Yiting Tang1, Lan Liu2, Ming Sheng3

  • 1College of Animal Science and Technology, Nanjing Agricultural University, Nanjing 210095, China; State Key Laboratory of Animal Nutrition and Key Laboratory of Farm Animal Genetic Resources and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China.

Insights

Knocking out Wip1 phosphatase inhibits mesenchymal stem cell (MSC) proliferation but enhances their migration via the PI3K/AKT/Rac1 pathway. This dual effect offers potential for targeted MSC therapies.

Area of Science:

  • Stem Cell Biology
  • Molecular Biology
  • Cell Signaling

Background:

  • Mesenchymal stem cells (MSCs) are valuable for therapy but face challenges with in vitro proliferation and senescence.
  • Understanding regulators of MSC migration is crucial for therapeutic applications.
  • Wild-type p53-inducible phosphatase-1 (Wip1) modulates phosphorylation, impacting cell processes.

Purpose of the Study:

  • To investigate the role of Wip1 in MSC proliferation and migration.
  • To elucidate the signaling pathways involved in Wip1-mediated MSC behavior.

Main Methods:

  • Generated Wip1 knockout (Wip1(-/-)) and wild-type (WT) MSCs.
  • Assessed proliferation, cell cycle, and migration using assays like Transwell and scratch.
  • Analyzed key signaling molecules including cyclinB1, Rac1, AKT, and filamentous-actin.

Main Results:

  • Wip1 knockout inhibited MSC proliferation and induced G2 cell-cycle arrest by reducing cyclinB1.
  • Wip1(-/-) MSCs exhibited enhanced migration compared to WT-MSCs.
  • Enhanced migration correlated with increased Rac1-GTP activity, pAKT/AKT ratio, actin rearrangement, and filopodia formation, mediated by the PI3K/AKT/Rac1 axis.

Conclusions:

  • Wip1 is essential for maintaining MSC proliferative capacity.
  • Wip1 deficiency enhances MSC migratory capacity through the PI3K/AKT/Rac1 pathway.
  • Targeting Wip1 offers a strategy for modulating MSC behavior for therapeutic purposes.